Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWOG S1616: Nivolumab + Ipilimumab vs Ipilimumab in Refractory Melanoma
NCT03033576Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in melanoma, sponsored by National Cancer Institute. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03033576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033576.